Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Jerry S. Wolinsky(The University of Texas Health Science Center at Houston), Douglas L. Arnold(McGill University), Jonathan Willmer(St. Michael's Hospital), Martin S. Weber(Fraunhofer Institute for Translational Medicine and Pharmacology), Sana Syed(St. Michael's Hospital), Emily C. Martin(St. Michael's Hospital), Fernando Dangond(Brigham and Women's Hospital), Ivan Staikov(St. Michael's Hospital), Karolina Piasecka‐Stryczynska(Poznan University of Medical Sciences)
Cited by 320
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k